

SUPPORTING INFORMATION

Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

Soumavo Mukherjee ¹, Dhananjay Suresh ¹, Ajit Zambre ², Sairam Yadavilli ¹, Shreya Ghoshdastidar ¹, Anandhi Upendran ³ and Raghuraman Kannan ^{1,2,4,*}

¹ Department of Bioengineering, University of Missouri, Columbia, MO 65211, USA


² Department of Radiology, University of Missouri, Columbia, MO 65212, USA

³ Department of Medical Pharmacology & Physiology, University of Missouri, Columbia, MO 65212, USA

⁴ Ellis Fischel Cancer Center, University of Missouri, Columbia, MO 65212, USA

* Correspondence: kannanr@health.missouri.edu

SUPPORTING FIGURES






Figure S2. Fluorescence analysis. Quantification of cytochrome-C fluorescence intensity in A549 cells before and after treatment with DAS or siAXL+DAS.